Download the presentation here: PDF
Download the presentation here: PDF
Download the presentation here: PDF
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Progenics / Wyeth: Making Opioids More Tolerant<br />
• RELISTOR decreases <strong>the</strong> constipating effects<br />
of opioids in patients with advanced illness who<br />
are receiving palliative care.<br />
• RELISTOR is <strong>the</strong> first selective peripherally<br />
acting mu–opioid receptor antagonist<br />
displacing opioid binding in tissues such as <strong>the</strong><br />
gastrointestinal tract.<br />
• RELISTOR does not diminish <strong>the</strong> central<br />
analgesic effects of opioids.<br />
• RELISTOR has a unique molecular structure<br />
that restricts it from crossing <strong>the</strong> blood-brain<br />
barrier.<br />
• In clinical studies, RELISTOR demonstrated:<br />
– No clinically relevant changes in pain<br />
scores from baseline.<br />
– No central opioid withdrawal.<br />
37<br />
www.wyeth.com<br />
© Defined Health, 2009<br />
Pain Insight Briefing<br />
Oral Relistor could enable <strong>the</strong><br />
franchise to address a potential<br />
$1B+ market opportunity in <strong>the</strong><br />
sizable adult chronic pain<br />
population, but previous<br />
challenges warrant caution.
Change language